DESTINY-Lung01: Phase II Trial of Trastuzumab Deruxtecan in HER2-Mutated Metastatic NSCLC

September 16-21, 2021; Virtual
In this single-arm study in patients with previously treated HER2-mutated NSCLC, trastuzumab deruxtecan demonstrated robust antitumor activity with a safety profile consistent with previous reports.
Format: Microsoft PowerPoint (.ppt)
File Size: 269 KB
Released: September 27, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Exelixis, Inc.
Ipsen Biopharmaceuticals, Inc.

Related Content

Clinical Care Options (CCO) commentary: Joel Neal, MD, discusses management of non-small-cell lung cancer (NSCLC) with uncommon EGFR mutations

Joel W. Neal, MD, PhD Released: May 20, 2022

On-demand webcast on biomarker-driven care for patients with NSCLC, from Clinical Care Options (CCO)

Todd M. Bauer, MD Sandip P. Patel, MD Joshua Sabari, MD Physicians: maximum of 1.75 AMA PRA Category 1 Credits Released: May 12, 2022 Expired: May 11, 2023

Downloadable slides for oncologists, pharmacists, and nurses: Immunotherapy and chemotherapy for extensive-stage SCLC from Clinical Care Options (CCO)

Released: May 11, 2022

On-demand webcast on HER2, HER3, and TROP2 antibody-drug conjugates in breast, gastrointestinal, and lung cancers, from Clinical Care Options (CCO)

Aditya Bardia, MD, MPH Yelena Y. Janjigian, MD Sandip P. Patel, MD Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: May 11, 2022 Expired: May 10, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings